ProtoKinetix has formulated a proprietary anti-aging glycopeptide with the potential to change lives through cell survival. The possibilities are endless, and we’ve only seen the tip of the iceberg.

  • Discovery


    Dr. Geraldine Castelot-Deliencourt invented AAGP® to be a smaller, more stable synthetic version of naturally occurring anti-freeze glycopeptides (AFGPs).
  • Patenting


    2004 to 2017
    ProtoKinetix filed patents for the use of AAGP® in clinical studies, including biologic material preservation, cryosurgery, pancreatic cell health and neurosensory precursor cell survival.
  • Research


    2016 to present
    A team of the world’s top scientists are studying AAGP®’s safety and effectiveness in cell cryopreservation, monoclonal antibody production and retinal cell replacement over time.
  • Results


    2016 to present
    Compared to control groups, pluripotent stem cells treated with AAGP® were 300% more viable when transplanted into retinal tissue and matured to the five-month milestone without compromise.

Invest in the future

If you could help find a cure for chronic conditions that affect our lives, what would that be worth to you? An investment in ProtoKinetix is an investment in your financial future and the future of health care. AAGP® could be used in multi-billion-dollar applications, touching millions of lives – starting with yours.

Ready to invest or just want to talk?

Investor & Stock News

The Annual Meeting of Stockholders of ProtoKinetix, Incorporated (the “Company”) occurred on February 11, 2022, at 4:00 p.m.

To watch the recording of the Shareholder Meeting, click below. 

Stock information

Investor testimonials

Create a secure online account

Find answers in our investor FAQ


Join us on our journey of cell survival

Get company news and research updates sent directly to your inbox.

Ready to invest?

Reach out and let’s talk about how we can help each other.

Image of bar graphs
Image of bar graphs